Conceivable Life Sciences

United States - New York, New York

• 16/01/2025
• Series A
• $18,000,000

Conceivable has developed the world’s first fully automated IVF lab. Our end-to-end reinvention of today’s largely manual, artisanal labs delivers new levels of precision, quality, and scalability. Simultaneously, Conceivable brings the innovation of modern cell therapies to IVF. We are already exceeding the clinical benchmarks of today’s best IVF labs.

Worldwide 95% of the infertile population–and 80% in the United States–don’t have access to IVF. Conceivable exists to change this. By automating the IVF lab we will vastly broaden the availability of this Nobel Prize winning therapy, improve results, and meet the demands of millions of infertile people wishing to achieve the dream of becoming parents.

Related People

Alan MurrayFounder

United States - New York, New York

I am the co-founder and CEO of Conceivable Life Sciences and we are pioneering the world’s first end-to-end automated IVF lab. Our application of artificial intelligence, machine learning, advanced imaging and optics, and robotics will improve results, increase access, and reduce costs.

For over two decades I have partnered with Joshua Abram and together we have co-founded a series of venture-backed companies.

They are recognized as category creators in diverse fields including technology, hospitality, and life sciences. Among the firms that we co-founded and led as early-stage Co-CEOs are Integral Ad Science (NASDAQ:IAS), NeueHouse, and TMRW Life Sciences.

As founders of Coriolis, we are also active early-stage investors with a history of providing the earliest capital to a series of startups that enjoyed exits through acquisitions by such firms as AT&T, Expedia and Greenthumb.

Since 2018, we have been investing extensively in disruptive technologies in the fertility space. As of December 2021, companies co-founded by me and Joshua had a market value of over $5 billion.

LinkedIn https://www.linkedin.com/in/alanleroymurray/